Breaking News Instant updates and real-time market news.

MTEM

Molecular Templates

$12.73

0.81 (6.80%)

, ALNA

Allena Pharmaceuticals

$2.31

0.01 (0.43%)

04:55
12/05/19
12/05
04:55
12/05/19
04:55

Evercore ISI to hold a conference

HealthCONx Conference 2019 will be held in Boston on December 3-5.

MTEM

Molecular Templates

$12.73

0.81 (6.80%)

ALNA

Allena Pharmaceuticals

$2.31

0.01 (0.43%)

MDGL

Madrigal Pharmaceuticals

$116.14

2.44 (2.15%)

PHG

Philips

$46.39

0.35 (0.76%)

QURE

uniQure

$65.39

1.52 (2.38%)

MBIO

Mustang Bio

$3.89

0.5 (14.75%)

SEEL

Seelos Therapeutics

$0.95

0.0863 (10.03%)

CYAD

Celyad

$12.71

0.56 (4.61%)

PFNX

Pfenex

$10.86

0.34 (3.23%)

STRO

Sutro Biopharma

$11.00

-0.16 (-1.43%)

AXNX

Axonics

$24.13

0.56 (2.38%)

NBSE

NeuBase Therapeutics

$6.93

0.05 (0.73%)

ZBH

Zimmer Biomet

$148.35

4.93 (3.44%)

ALIM

Alimera Sciences

$7.16

0.41 (6.07%)

INSM

Insmed

$23.36

0.4 (1.74%)

ADMS

Adamas Pharmaceuticals

$6.40

-0.12 (-1.84%)

AXGT

Axovant

$5.20

0.08 (1.56%)

BCEL

Atreca

$13.00

-0.285 (-2.15%)

MYOV

Myovant Sciences

$17.30

-1.26 (-6.79%)

PIRS

Pieris Pharmaceuticals

$3.93

0.03 (0.77%)

MYL

Mylan

$18.89

0.365 (1.97%)

RCKT

Rocket Pharmaceuticals

$19.22

0.88 (4.80%)

CBAY

CymaBay

$1.66

-0.01 (-0.60%)

NBIX

Neurocrine

$118.67

1.08 (0.92%)

TCDA

Tricida

$39.62

0.09 (0.23%)

NTLA

Intellia Therapeutics

$17.67

0.59 (3.45%)

ALKS

Alkermes

$21.24

0.98 (4.84%)

  • 05

    Dec

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 11

    Dec

MTEM Molecular Templates
$12.73

0.81 (6.80%)

12/10/18
OPCO
12/10/18
INITIATION
Target $15
OPCO
Outperform
Molecular Templates initiated with an Outperform at Oppenheimer
Oppenheimer analyst Kevin DeGeeter started Molecular Templates with an Outperform rating and $15 price target. The analyst believes Molecular's Engineered Toxin Bodies platform offers a differentiated mechanism of action that will be attractive to pharma and drive partnerships in 2019 and 2020.
04/29/19
UBSW
04/29/19
INITIATION
Target $12
UBSW
Buy
Molecular Templates initiated with a Buy at UBS
UBS analyst Carger Gould initiated Molecular Templates with a Buy rating and a price target of $12, citing the company's "development stage oncology" position that is seeking to leverage "the biology of Shiga-like toxins to generate antibody-fragments with differentiated profiles." The analyst is positive on Molecular Templates' "optionality for molecular templates across targets not currently addressable or inadequately addressed by antibody drug conjugates," adding that its lead asset MT-3724 is being "incrementally de-risked with lymphoma" this year.
ALNA Allena Pharmaceuticals
$2.31

0.01 (0.43%)

09/06/19
FBCO
09/06/19
NO CHANGE
Target $7
FBCO
Outperform
Allena Pharmaceuticals price target lowered to $7 from $26 at Credit Suisse
Credit Suisse analyst Martin Auster lowered his price target for Allena Pharmaceuticals and maintained an Outperform rating after taking a fresh look at reloxaliase ahead of uriROX-1 Phase 3 results expected in Q4. While Auster thinks this trial has a solid likelihood of being positive and views it as a meaningful catalyst for the name, he lowered his peak sales estimate for reloxaliase to $250M from $900M.
11/07/19
BARD
11/07/19
NO CHANGE
Target $20
BARD
Outperform
Allena Pharmaceuticals selloff today a buying opportunity, says Baird
Baird analyst Madhu Kumar views the selloff today in shares of Allena Pharmaceuticals as a buying opportunity. With reloxaliase meeting the primary endpoint of urinary oxalate reductions versus placebo with an absolute 22.6% urinary oxalate decline from baseline, the analyst believes the URIROX-1 trial reads positively to the second Phase 3 trial, URIROX-2. He reiterates an Outperform rating on Allena with a $20 price target. The analyst believes the market's reaction is wrong with the stock down 47% to $3.08.
11/07/19
ROTH
11/07/19
NO CHANGE
Target $31
ROTH
Buy
Allena's high placebo result in URIROX-1 a 'red herring,' says Roth Capital
Roth Capital analyst Yasmeen Rahimi tells investors in a research note that she thinks Allena Pharmaceuticals is getting "unnecessarily punished" on Thursday following positive URIROX-1 topline data on the basis of higher placebo response, smaller treatment effect and next steps for securing regulatory approval, saying she thinks URIROX-1 data tees up with URIROX-2 for success. In her view, the higher than expected placebo result is a "complete red herring," and keeps a Buy rating and $31 price target on the shares.
11/08/19
RILY
11/08/19
NO CHANGE
Target $11
RILY
Buy
Allena Pharmaceuticals selloff yesterday overdone, says B. Riley FBR
B. Riley FBR analyst Mayank Mamtani lowered his price target for Allena Pharmaceuticals to $11 from $20 saying clinical meaningfulness of reloxaliase's effect remains to be answered in the second Phase III URIROX-2 study. This increases skepticism around its market opportunity, says Mamtani, who cut his penetration assumption by half, driving his peak sales estimate to $183M from $367M. The analyst, whoever, views yesterday's selloff as overdone and keeps a Buy rating on Allena Pharmaceuticals.
MDGL Madrigal Pharmaceuticals
$116.14

2.44 (2.15%)

06/10/19
RILY
06/10/19
UPGRADE
Target $134
RILY
Buy
Madrigal Pharmaceuticals upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst Mayank Mamtani upgraded Madrigal Pharmaceuticals to Buy from Neutral and raised his price target for the shares to $134 from $128. The analyst believes the company's nonalcoholic steatohepatitis programs are "uniquely designed for maximize success."
06/25/19
STFL
06/25/19
INITIATION
Target $126
STFL
Hold
Madrigal Pharmaceuticals initiated with a Hold at Stifel
Stifel analyst Derek Archila initiated Madrigal Pharmaceuticals (MDGL) with a Hold rating and $126 price target, stating that he is positively biased heading into Phase 3 amid emerging evidence that point to the possibility resmetirom could demonstrate a benefit on fibrosis over time. However, he thinks the stock could be volatile around updates from competitors such as Viking Therapeutics (VKTX) and Genfit (GNFT) and sees few catalysts specific to Madrigal to drive shares up in the next 12-18 months, Archila tells investors.
09/17/19
SBSH
09/17/19
NO CHANGE
Target $173
SBSH
Buy
Madrigal Pharmaceuticals price target lowered to $173 from $186 at Citi
Citi analyst Joel Beatty lowered his price target for Madrigal Pharmaceuticals to $173 from $186 while maintaining a Buy rating on the shares. The analyst reduced his launch estimates for Resmetirom, saying it appears that there's a near-term lack of progress on non-invasive diagnostics for nonalcoholic steatohepatitis. The analyst expects non-invasive diagnostics to become the standard for diagnosing NASH but is not confident that they will be widely adopted early on in the launch of the first NASH drugs. However, he continues to view Madrigal's Resmetirom as one of the most promising agents in later-stage development for the treatment of earlier-stage NASH, particularly those with dyslipidemia.
12/02/19
SBSH
12/02/19
NO CHANGE
Target $166
SBSH
Buy
Madrigal Pharmaceuticals price target lowered to $166 from $173 at Citi
Citi analyst Joel Beatty lowered his price target for Madrigal Pharmaceuticals to $166 from $173 while maintaining a Buy rating on the shares. He continues to believe that Madrigal's Resmetirom is one of the most promising agents in later-stage development for the treatment of earlier-stage nonalcoholic steatohepatitis, particularly those with dyslipidemia. The analyst expects the stock to trade up as the ongoing Phase 3 study progresses, possibly completing enrollment in 2020.
PHG Philips
$46.39

0.35 (0.76%)

04/16/19
BTIG
04/16/19
DOWNGRADE
BTIG
Neutral
Masimo downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded Masimo (MASI) to Neutral mainly on valuation concerns, stating that while nothing has changed in his positive expectations for the company's performance, the stock may be "running out of steam". The analyst believes that Masimo should continue "taking market share, post strong revenue growth supported by multiple drivers, and enjoy adoption uplift through the Philips (PHG) co-marketing deal", but also sees the valuation on the stock reflecting "a good deal of the good news".
07/30/19
SBSH
07/30/19
INITIATION
SBSH
Buy
Philips initiated with a Buy at Citi
Citi analyst Kate Kalashnikova started Philips with a Buy rating and 49 euros price target. The expects the company's earnings momentum in diagnosis and treatment to continue as well as its recovery in personal health.
07/30/19
07/30/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tencent Music (TME) initiated with an Outperform at Oppenheimer. 2. Medallia (MDLA) initiated with an Overweight at Stephens. 3. Fanhua (FANH) initiated with an Overweight at Morgan Stanley. 4. Philips (PHG) initiated with a Buy at Citi. 5. Freshpet (FRPT) initiated with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
QURE uniQure
$65.39

1.52 (2.38%)

12/03/19
GSCO
12/03/19
INITIATION
Target $98
GSCO
Buy
uniQure initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Salveen Richter initiated coverage of uniQure with a Buy rating and $98 price target. uniQure is a clinical-stage gene therapy company targeting liver and central nervous system disorders and developed the first commercial gene therapy, Glybera, Richter tells investors in a research note. The analyst is positive on the company's lead program AMT-061 in hemophilia B. Further, he views the Huntington's disease program as the next key value driver with first safety/biomarker data in 2020.
12/03/19
COWN
12/03/19
INITIATION
COWN
Outperform
uniQure initiated with an Outperform at Cowen
Cowen analyst Joseph Thome initiated coverage of uniQure with an Outperform rating.
12/03/19
12/03/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Facebook (FB) and Alphabet (GOOG, GOOGL) initiated with an Overweight at Piper Jaffray. 2. Ulta Beauty (ULTA) resumed with a Buy at Deutsche Bank. 3. Beyond Meat (BYND) initiated with a Perform at Oppenheimer. 4. uniQure (QURE) was initiated with a Buy at Goldman Sachs and an Outperform at Cowen. 5. Enphase Energy (ENPH) initiated with a Buy at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/03/19
PIPR
12/03/19
NO CHANGE
Target $80
PIPR
Overweight
uniQure a name 'investors need to own,' says Piper Jaffray
After speaking with CEO Matt Kapusta for a fireside chat today, Piper Jaffray analyst Danielle Brill says uniQure is a name that "investors need to own." The analyst reiterates an Overweight rating on the shares with an $80 price target. The company is approaching catalysts for AMT-061 in hemophilia B and first in-human Huntington's disease data with AMT-130 expected in 2020, Brill tells investors in a research note. She believes uniQure's "deep" pipeline and in-house manufacturing capabilities differentiate it from other gene therapy companies.
MBIO Mustang Bio
$3.89

0.5 (14.75%)

06/20/19
CANT
06/20/19
INITIATION
Target $7
CANT
Overweight
Mustang Bio initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros initiated Mustang Bio with an Overweight and $7 price target.
06/21/19
CANT
06/21/19
INITIATION
Target $7
CANT
Overweight
Cantor starts Mustang Bio with Overweight rating, $7 price target
Cantor Fitzgerald analyst Elemer Piros last night initiated coverage of Mustang Bio with an Overweight rating and $7 price target. The company's pipeline centers on various gene and cell therapies are partnered with leading academic foundations, Piros tells investors in a research note. The analyst believes this approach of in-licensing these assets "may lift initial risks for future clinical development."
08/13/19
HCWC
08/13/19
INITIATION
Target $7
HCWC
Buy
Mustang Bio initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis started Mustang Bio with a Buy rating and $7 price target. The analyst believes Mustang has a high probability of clinical success and that its "strong" academic partnerships may lead to "high quality" clinical data and provide additional funding while decreasing potential shareholder dilution. These factors highlight a "valuation disconnect for investors currently looking for compelling opportunities in an overcrowded biotech arena," Pantginis tells investors in a research note.
11/20/19
CANT
11/20/19
INITIATION
Target $7
CANT
Overweight
Mustang Bio assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Kristen Kluska assumed coverage of Mustang Bio with an Overweight rating and $7 price target. The analyst believes XSCID is the main value driver for Mustang shares and she sees an imminent catalyst in guidance on the regulatory pathway forward.
SEEL Seelos Therapeutics
$0.95

0.0863 (10.03%)

05/10/19
HCWC
05/10/19
INITIATION
Target $4
HCWC
Buy
Seelos Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright started Seelos Therapeutics with a Buy rating and $4 price target.
05/14/19
ROTH
05/14/19
INITIATION
Target $8
ROTH
Buy
Seelos Therapeutics initiated with a Buy at Roth Capital
Roth Capital analyst Yasmeen Rahimi started coverage of Seelos Therapeutics with a Buy rating and $8 price target. The analyst says the company has an "enriched" pipeline, with numerous milestones in 2019 and top-line results from PK/PD of SLS-002 to treat acute suicidality in early 2020.
11/14/19
BNCH
11/14/19
INITIATION
Target $4
BNCH
Speculative Buy
Seelos Therapeutics initiated with a Speculative Buy at Benchmark
Benchmark analyst Bruce Jackson initiated coverage of Seelos Therapeutics with a Speculative Buy rating and $4 price target. The early-stage company's lead product candidate, SLS-002 for the treatment of suicidality in Major Depressive Disorder and Post Traumatic Stress Disorder, is looking to enter a potential market of more than $1B, noted Jackson. The completion of a Phase 1 study of SLS-002 is expected in the first quarter of 2020, to be followed by the start of a Phase 2 proof of concept trial in the second quarter, he added.
11/18/19
HCWC
11/18/19
NO CHANGE
Target $2
HCWC
Buy
Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
H.C. Wainwright analyst Vernon Bernardino halved his price target for Seelos Therapeutics to $2 from $4 after lowering his probability of success in the SLS-002 program to 30% from 38%. He believes increased caution in expectations for SLS-002 is merited and but keeps a Buy rating on Seelos shares.
CYAD Celyad
$12.71

0.56 (4.61%)

06/17/19
PIPR
06/17/19
NO CHANGE
PIPR
Piper Jaffray reiterates Overweight on Celyad after EHA update
Piper Jaffray analyst Edward Tenthoff reiterated an Outperform rating and $41 price target on Celyad after the company presented updated data for Phase I THINK and DEPLETHINK at the European Hematology Association, or EHA. Tenthoff noted that the updated Phase I THINK study now shows 4/13, or 31%, evaluable r/r AML patients achieved objective responses on CYAD-01 monotherapy without preconditioning with manageable safety, while the Phase I DEPLETHINK study demonstrated 2/5 evaluable patients achieved SD on CYAD-01 with pre-conditioning regiment of cyclphosphamide and fludarabine at the same three dose level as in THINK. The analyst added that Celyad could potentially initiate a registrational Phase II AML study in the second half of the year.
06/17/19
RHCO
06/17/19
NO CHANGE
RHCO
Celyad selloff a buying opportunity, says SunTrust
SunTrust analyst Peter Lawson reiterated a Buy rating and $45 price target on Celyad after the stock dropped by almost 29% post-EHA, or European Hematology Association. The analyst sees this as a buying opportunity, as he believes it is undervalued, and also believes the year-end data is more important to the stock than the current headline data, which he said is "too early" and doesn't warrant a selloff.
07/05/19
PIPR
07/05/19
NO CHANGE
Target $25
PIPR
Overweight
Celyad price target lowered to $25 from $41 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target on Celyad to $25 from $41 after the company presented preliminary interim data from the ongoing SHRINK and alloSHRINK Phase 1 trials of the NKG2D-based CAR-T therapies CYAD-01 and CYAD-101 for the treatment of metastatic colorectal cancer at the European Society for Medical Oncology Congress. He believes Celyad will prioritize development of an allogeneic CAR-T in solid tumors given there was no clinical evidence of Graft versus Host Disease and anticipates the next alloSHRINK update by year-end 2020. Tenthoff cites pushing out approval expectations for his lowered price target, but keeps an Overweight rating on Celyad shares.
07/05/19
HCWC
07/05/19
NO CHANGE
Target $48
HCWC
Buy
Celyad target lowered to $48 on new launch timeline at H.C. Wainwright
H.C. Wainwright analyst Edward White lowered his price target for Celyad to $48 from $52 after Celyad presented updates on CYAD-01 and CYAD-101. Both studies showed disease control with patients exhibiting partial response and stable disease, White tells investors in a research note. And importantly, both therapies were well tolerated as there were no reports of cytokine syndrome release Grade 2 or higher, and no serious adverse events, dose-limiting toxicities nor on-target off-tumor toxicity, adds the analyst. The analyst trimmed his price target after moving back his launch expectation for CYAD-01 to 2024. White keeps a Buy rating on the shares.
PFNX Pfenex
$10.86

0.34 (3.23%)

04/02/19
WELS
04/02/19
NO CHANGE
Target $68
WELS
Market Perform
BARDA passing on Pfenex good news for Emergent, says Wells Fargo
The decision by the Department of Health and Human Services' Biomedical Advanced Research and Development Authority not to exercise development options on Pfenex's (PFNX) anthrax program is good news for Emergent BioSolutions (EBS), Wells Fargo analyst David Maris tells investors in a research note. Emergent currently sells BioThrax, a vaccine indicated for the active immunization for the prevention of disease caused by anthrax, Maris points out. In addition, NuThrax is the company's most important pipeline product as it represents an improvement on BioThrax, says the analyst. He sees the move by BARDA on the Pfenex program as underscoring its belief in the BioThrax and NuThrax programs. Maris keeps a Market Perform rating on Emergent BioSolutions with a $68 price target. The stock in early trading is up 58c to $50.81.
09/11/19
JMPS
09/11/19
NO CHANGE
Target $17
JMPS
Outperform
Pfenex price target raised to $17 from $13 at JMP Securities
JMP Securities analyst Jason Butler raised his price target on Pfenex to $17 and kept his Outperform rating, saying its platform potential is becoming increasingly "visible and validated". The analyst cites the company's lead candidate PF708 progressing toward approval, with a possible Q4 commercial launch. Butler notes that Pfenex now has the opportunity for increased focus on additional pipeline programs such as PF743/PF745 and CRM197, which have "already demonstrated value."
10/24/19
CANT
10/24/19
INITIATION
Target $20
CANT
Overweight
Pfenex initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Bradon Folke initiated coverage of Pfenex with an Overweight rating and $20 price target.
10/25/19
CANT
10/25/19
INITIATION
Target $20
CANT
Overweight
Cantor starts Pfenex at Overweight, sees 'significant value' despite run
Cantor Fitzgerald analyst Bradon Folke last night initiated coverage of Pfenex with an Overweight rating and $20 price target. The company has "regenerated itself to a position that presents a compelling investment opportunity" for investors going into 2020, Folke tells investors in a research note. Even though the stock is up 150% year-to-date, Pfenex continues to have "significant value" which can still be unlocked over the coming 12-18 months through data readouts, as well as the potential therapeutic equivalent rating and launch of PF708, contends the analyst. He expects data readouts, approvals, and upward earnings revisions to drive the stock higher.
STRO Sutro Biopharma
$11.00

-0.16 (-1.43%)

07/18/19
DBAB
07/18/19
INITIATION
Target $22
DBAB
Buy
Sutro Biopharma initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Konstantinos Aprilakis started Sutro Biopharma with a Buy rating and $22 price target. The analyst initiated coverage on eight smid-cap Biotechnology stocks in the oncology space.
09/05/19
JMPS
09/05/19
INITIATION
Target $16
JMPS
Outperform
Sutro Biopharma resumed with an Outperform at JMP Securities
JMP Securities analyst Reni Benjamin resumed coverage of Sutro Biopharma with an Outperform rating and a price target of $16, adding that the bull case price target on the stock is $24. The analyst believes that the company has the potential to generate $767M in sales by 2029 thanks to its "combination of potential collaboration agreement revenues, risk-adjusted revenues from lead antibody drug conjugate candidates STRO-001 and STRO-002, and royalties from BCMA ADC." Benjamin contends that Sutro Biopharma shares are "attractively priced" given the company's "multiple high-profile partners" and a cash balance of $168M.
10/07/19
BTIG
10/07/19
INITIATION
Target $19
BTIG
Buy
Sutro Biopharma initiated with a Buy at BTIG
BTIG analyst Thomas Shrader initiated Sutro Biopharma (STRO) with a Buy rating and a price target of $19. The analyst cites the company's efforts in improving the "rapid DNA-to-protein cycle times of cell free biosynthesis", which have already yielded $350M in partnership funding with another up to $2.5B to come. Shrader sees the work on BCMA-ADC with Celgene (CELG) and the engineered cytokines with Merck (MRK) as "particularly interesting" because of their "unmet need" potential.
10/07/19
10/07/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. SmileDirectClub (SDC) initiated with an Outperform at Credit Suisse and William Blair, an Overweight rating at JPMorgan, and a Buy at Loop Capital, Citi, Jefferies, BTIG, Guggenheim, BofA/Merrill, and Stifel. 2. SJW Corp. (SJW) initiated with an Outperform rating at Macquarie. 3. FleetCor (FLT) initiated with a Sector Perform at RBC Capital. 4. Gladstone Land (LAND) initiated with a Buy rating at Aegis. 5. Sutro Biopharma (STRO) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
AXNX Axonics
$24.13

0.56 (2.38%)

10/21/19
LEHM
10/21/19
INITIATION
Target $43
LEHM
Overweight
Axonics initiated with an Overweight at Barclays
Barclays analyst Kristen Stewart initiated coverage of Axonics Modulation Technologies (AXNX) with an Overweight rating and $43 price target. Axonics is entering the $650M sacral neuromodulation market, where Medtronic (MDT) has enjoyed a monopoly for more than 20 years, Stewart tells investors in a research note. The analyst sees Axonics as a "sales execution story." With a "superior product," the company can gain share and expand the market, says Stewart.
11/01/19
PIPR
11/01/19
INITIATION
Target $39
PIPR
Overweight
Axonics initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Adam Maeder initiated coverage of Axonics Modulation Technologies (AXNX) with an Overweight rating and $39 price target. Although there is some investor disappointment that U.S. launch didn't commence sooner and urinary approval is still pending, Axonics remains positioned for commercial success and "strong" sales growth next year, Maeder tells investors in a research note. He believes the company's r-SNM has meaningful advantages over Medtronic's (MDT) InterStim II product and sees "plenty of room in the market for a second competitor."
11/04/19
PIPR
11/04/19
NO CHANGE
Target $39
PIPR
Overweight
Axonics doctor checks suggest 'meaningful share capture,' says Piper Jaffray
Piper Jaffray analyst Adam Maeder says his checks at the Axonics Modulation Technologies physician seminar in Dallas this past weekend suggest "meaningful share capture" for the company's r-SNM system. The analyst left the seminar with increased confidence in his U.S. share and revenue forecasts for 2020 and 2021. He reiterates an Overweight rating on Axonics shares with a $39 price target.
11/05/19
PIPR
11/05/19
NO CHANGE
PIPR
Overweight
Medtronic filed patent lawsuit against Axonics, says Piper Jaffray
Piper Jaffray analyst Adam Maeder says Medtronic (MDT) yesterday filed a lawsuit with the U.S. District Court for the Central District of California alleging that Axonics Modulation Technologies' rechargeable sacral neuromodulation system infringes its U.S. patents. As part of the lawsuit, Medtronic is seeking injunctive relief and damages for alleged intellectual property infringement, the analyst points out. The timing of the lawsuit coincides with Axonics' U.S. commercial launch, says Maeder, who points out that patent litigation is not uncommon in the medical device sector and generally takes a while to play out. He expects Axonics to "defend itself vigorously and continue to sell r-SNM throughout the ongoing legal process."
NBSE NeuBase Therapeutics
$6.93

0.05 (0.73%)

09/24/19
BTIG
09/24/19
INITIATION
Target $15
BTIG
Buy
NeuBase Therapeutics initiated with a Buy at BTIG
BTIG analyst Thomas Shrader started NeuBase Therapeutics with a Buy rating and $15 price target. Parts of the NeuBase platform as risk-mitigated and collectively contributing to a next-generation iteration of peptide nucleic acids, Shrader tells investors in a research note. He believes the company's novel PNA platform is "primed" to attract" impressive partners" that could provide non-dilutive capital.
10/29/19
HCWC
10/29/19
INITIATION
Target $14
HCWC
Buy
NeuBase Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of NeuBase Therapeutics with a Buy rating and $14 price target. The company's platform has broad applicability, since it utilizes peptide-nucleic acid constructs that can achieve what cannot be accomplished using standard antisense oligonucleotides, contends the analyst.
11/20/19
OPCO
11/20/19
INITIATION
Target $14
OPCO
Outperform
NeuBase Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Hartaj Singh initiated coverage of NeuBase Therapeutics with an Outperform rating and $14 price target. The analyst believes the company has "solved for many technical limitations to first-generation antisense oligonucleotides" and is bullish on NeuBase's approach with lead molecules NT0100 for Huntington's disease and NT0200 for myotonic dystrophy.
ZBH Zimmer Biomet
$148.35

4.93 (3.44%)

11/06/19
LEER
11/06/19
NO CHANGE
Target $160
LEER
Outperform
Zimmer Biomet price target raised to $160 from $155 at SVB Leerink
SVB Leerink analyst Richard Newitter raised his price target for Zimmer Biomet to $160 from $155, saying Zimmer represents an attractive turnaround story at a compelling valuation and is one of his favorite large-cap picks, especially as revenue growth acceleration looks set to start taking form in a more meaningful way into 2020-2021. Newitter says the company's quarterly performance, plus management's commentary that it sees a pathway for acceleration beyond 2%-3% for 2020 without the need for M&A increases his confidence in an upward estimate revision bias towards his above-consensus out-year estimates. The analyst keeps an Outperform rating on the shares.
11/06/19
RAJA
11/06/19
NO CHANGE
Target $160
RAJA
Outperform
Zimmer Biomet price target raised to $160 from $150 at Raymond James
Raymond James analyst Lawrence Keusch raised his price target for Zimmer Biomet to $160 from $150 and maintained an Outperform rating following the company's "solid' Q3 results, which he says supports a story of incremental improvement for a company with leading global market share and a management team focused on execution.
12/04/19
RAJA
12/04/19
UPGRADE
Target $170
RAJA
Strong Buy
Zimmer Biomet upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Lawrence Keusch upgraded Zimmer Biomet to Strong Buy from Outperform with a $170 price target.
12/04/19
RAJA
12/04/19
UPGRADE
Target $170
RAJA
Strong Buy
Zimmer Biomet upgraded to Strong Buy at Raymond James, PT raised to $170
Raymond James analyst Lawrence Keusch upgraded Zimmer Biomet to Strong Buy from Outperform with a price target of $170, up from $160. In a research note to investors, Keusch says that while accelerating growth has underpinned his prior positive rating, opportunities to reduce obsolete inventory charges and inventory over the next several years increase his conviction in further shareholder value creation. The analyst calls out Zimmer's annual inventory charges, which are well above large-cap comparables at over $200M. He further states that the potential for an inflection in free cash flow and potential EPS upside may not yet be fully appreciated by investors as it is early and the shares under-owned by large long-only investors, improving fundamentals and cash flow dynamics could drive incremental ownership.
ALIM Alimera Sciences
$7.16

0.41 (6.07%)

05/28/19
CHLM
05/28/19
INITIATION
Target $3
CHLM
Buy
Alimera Sciences initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Alexander Nowak started coverage of Alimera Sciences with a Buy rating and a $3 price target. The analyst believes novel DME therapy is positioned to accelerate revenue growth, and take market share. Further, he notes that established solution with new indications and data are coming.
09/30/19
RILY
09/30/19
NO CHANGE
Target $2
RILY
Buy
Alimera checks show 'substantial' recovery in Q3, says B. Riley FBR
B. Riley FBR analyst Andrew D'Silva says his channel checks related to Iluvien over the past two weeks, including calls with some of Alimera Sciences' new sales reps and retinal specialists, show a "substantial" quarter-over-quarter recovery. The due diligence makes the analyst "incrementally more confident" on Alimera being able to post a "significant recovery" in Q3 following the shortfall in Q2. D'Silva, who views the Q3 consensus revenue estimate as beatable, continues to believe Alimera is "significantly undervalued." He reiterates a Buy rating on the shares with a $2.00 price target.
INSM Insmed
$23.36

0.4 (1.74%)

03/26/19
STFL
03/26/19
NO CHANGE
Target $43
STFL
Buy
Pulmonologist call reinforces Stifel view of upside for Insmed
After hosting a conference call with two key opinion leader pulmonologists to discuss the rollout of Arikayce, Stifel analyst Adam Walsh said their feedback suggested the strong start for the drug was not the result of a "bolus" of patients awaiting approval and noted that both doctors said their new-patient starts remain steady. While it "remains early days in the launch," the call with the doctors reinforced his belief that Insmed's Arikayce guidance is likely conservative, Walsh tells investors. He keeps a Buy rating and $43 price target on Insmed shares.
04/09/19
HCWC
04/09/19
NO CHANGE
Target $52
HCWC
Buy
Insmed price target raised to $52 from $43 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised his price target for Insmed to $52 from $43 saying the company yesterday announced a positive update on the U.S. launch of Arikayce. The broadening of the prescriber base "is not short lived and can continue, as well as possibly be supplemented by label expansion into first line patients," Fein tells investors in a research note. He keeps a Buy rating on the shares.
08/01/19
STFL
08/01/19
NO CHANGE
Target $43
STFL
Buy
Insmed selloff 'decidedly overdone,' says Stifel
Stifel analyst Adam Walsh notes that despite another "strong beat and raise quarter," Insmed's shares are trading off, which is likely attributable to persistent concerns regarding future Arikayce drop-outs leading to a flattening of the growth curve, some timing uncertainty on the front-line trial launch, and the recent capital raise done at $26/share and related selling pressure based on that alone. On drop-outs, the analyst acknowledges lack of long-term visibility but believes the rate thus far has been better than expected. On the PRO measure, Walsh believes it is "critically important" for Insmed to "get it right," given the large font-line opportunity. Overall, the analyst sees the selloff as "decidedly overdone" in light of the continued strong Arikayce launch execution and encouraging forward guidance. Walsh reiterates a Buy rating and $43 price target on the shares.
09/03/19
GSCO
09/03/19
INITIATION
Target $30
GSCO
Buy
Insmed initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Graig Suvannavejh initiated Insmed with a Buy rating and a price target of $30, saying the stock offers an attractive entry point at 50% below its 52-week high as a de-risked commercial-stage biopharma with "significant" potential for expansion. The analyst contends that Insmed's lead orphan lung disease product Arikayce is well-positioned with it's early life cycle stage, no obvious competition and the potential for both geographic and label expansion. Suvannavejh adds that the company's INS1007 also has pipeline potential while garnering "little investor attention".
ADMS Adamas Pharmaceuticals
$6.40

-0.12 (-1.84%)

09/09/19
09/09/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CrossFirst Bancshares (CFB) initiated with an Outperform at Keefe Bruyette and a Market Perform at Raymond James. 2. Murphy Oil (MUR) initiated with an Overweight at KeyBanc. 3. resTORbio (TORC) initiated with an Overweight at Cantor Fitzgerald while Adamas Pharmaceuticals (ADMS) was initiated with a Neutral. 4. Altice USA (ATUS) initiated with a Buy at Benchmark. 5. Perficient (PRFT) initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/30/19
BOFA
09/30/19
DOWNGRADE
BOFA
Underperform
Adamas Pharmaceuticals downgraded to Underperform from Neutral at BofA/Merrill
09/30/19
BOFA
09/30/19
DOWNGRADE
Target $5
BOFA
Underperform
Adamas Pharmaceuticals downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad downgraded Adamas Pharmaceuticals (ADMS) to Underperform and lowered his price target to $5 from $9. The analyst cites indications of a "limited" uptake of ADS-5102 by doctors in multiple sclerosis, adding that the drug's phase 2 trial data have demonstrated comparable response and more safety concerns than the current standard-of-care with Ampyra made by Acorda Therapeutics (ACOR). Ahmad is also increasing his discontinuation rate assumption for '5102 to 30% and lowers his risk-adjusted peak sales estimate to $324M from $365M.
11/08/19
JMPS
11/08/19
NO CHANGE
Target $16
JMPS
Outperform
Adamas Pharmaceuticals price target lowered to $16 from $57 at JMP Securities
JMP Securities analyst Jason Butler lowered his price target on Adamas Pharmaceuticals to $16 after its Q3 earnings miss driven by higher than expected SG&A expenses and slightly-below-consensus GOCOVRI sales. The analyst still keeps his Outperform rating on confidence that the "refreshed" management team can reinvigorate the GOCOVRI launch but lowers his projected peak penetration sales to $250M from $550M. Butler is also removing the ADS-4101 from his model until there is more clarity on its path forward.
AXGT Axovant
$5.20

0.08 (1.56%)

06/06/19
JMPS
06/06/19
NO CHANGE
Target $28
JMPS
Outperform
Axovant price target raised to $28 after reverse split at JMP Securities
JMP Securities analyst Jason Butler raised his price target on Axovant shares to $28 from $8 to account for the stock's 1-for-8 reverse split and other share count changes. Additionally, he noted that he is enthused by the sustained improvements in OFF score that were reported at six months in the first cohort in the ongoing SUNRISE-PD Phase 2 trial in Parkinson's disease. Butler keeps an Outperform rating on Axovant shares, telling investors that today's updated results give him greater confidence in both the consistency and durability of benefits for AXO-Lenti-PD.
06/21/19
LEER
06/21/19
INITIATION
Target $18
LEER
Outperform
Axovant initiated with an Outperform at SVB Leerink
SVB Leerink initiated Axovant with an Outperform and $18 price target.
08/12/19
BARD
08/12/19
UPGRADE
Target $13
BARD
Outperform
Axovant upgraded to Outperform from Neutral at Baird
Baird analyst Brian Skorney upgraded Axovant Gene Therapies to Outperform from Neutral while lowering his price target for the shares to $13 from $16.
08/12/19
BARD
08/12/19
UPGRADE
Target $13
BARD
Outperform
Axovant upgraded to Outperform at Baird
As reported previously, Baird analyst Brian Skorney upgraded Axovant to Outperform from Neutral. The analyst cited excitement over the upcoming release of its gene-therapy data. He believes success in anyone of its three ongoing gene therapy programs would represent significant upside to today's value. Skorney lowered his price target to $13 from $16 on Axovant shares.
BCEL Atreca
$13.00

-0.285 (-2.15%)

07/15/19
ADAM
07/15/19
INITIATION
Target $23
ADAM
Buy
Atreca initiated with a Buy at Canaccord
Canaccord analyst John Newman initiated Atreca with a Buy rating as its ATRC-101 preclinical trial data suggests activity across multiple solid tumor cancers. If successful, peak sales could reach roughly $1.4B globally. Newman has a $23 price target on Atreca shares.
07/15/19
COWN
07/15/19
INITIATION
COWN
Outperform
Atreca initiated with an Outperform at Cowen
Cowen analyst Philip Nadeau initiated Atreca with an Outperform rating citing its lead candidate ATRC-101 first-in-class antibody that has been shown to activate the immune system to potently attack tumors in preclinical models.
07/15/19
07/15/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Slack Technologies (WORK) initiated with an Outperform at William Blair, an Overweight at Barclays, and a Buy at Canaccord. 2. Grocery Outlet (GO) initiated with an Outperform at Telsey Advisory and Cowen, a Buy at Jefferies, an Equal Weight at Morgan Stanley, as well as a Neutral at Goldman Sachs, BofA/Merrill, and Guggenheim. 3. Atreca (BCEL) initiated with an Outperform at Evercore ISI and Cowen, as well as a Buy at Stifel. 4. Aqua America (WTR) initiated with a Buy at BofA/Merrill. 5. Anaplan (PLAN) initiated with an Outperform at Macquarie. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/04/19
ROTH
09/04/19
INITIATION
Target $30
ROTH
Buy
Atreca initiated with a Buy at Roth Capital
Roth Capital analyst Tony Butler initiated Atreca with a Buy rating and a price target of $30. The analyst cites the potential commercial opportunity for the company's lead product candidate ATRC-101, which is unique from most targeted anti-cancer therapeutic antibodies in that it is derived from antibodies against tumors from patients who experienced an active, and clinically meaningful immune response against their tumors. Butler models peak risk-adjusted sales for ATRC-101 at $850M in non-small cell lung cancer, or NSCLC, estimating some 540K patients diagnosed with lung cancer in U.S. and Europe this year, of which 85-90% will be NSCLC.
MYOV Myovant Sciences
$17.30

-1.26 (-6.79%)

08/28/19
GSCO
08/28/19
NO CHANGE
Target $110
GSCO
Buy
Slower Orilissa ramp has minimal impact on Neurocrine, says Goldman Sachs
To reflect the slower than expected ramp in sales of Orilissa in endometriosis, Goldman Sachs analyst Paul Choi lowered his Neurocrine Biosciences (NBIX) forecasts of Orilissa royalties. He projects similar 40% market share by 2026 for both Myovant Sciences' (MYOV) relugolix and Orilissa within endometriosis and uterine fibroid patients treated with a GnRH receptor antagonists. However, in the near-term, since Orilissa royalties are a small fraction of Neurocrine's revenue, these changes have little impact on the company's top- and bottom- lines, says Choi. As such, the analyst keeps a Buy rating on Neurocrine Biosciences with a $110 price target.
08/28/19
08/28/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cerus (CERS) initiated with a Buy at Stifel. 2. DouYu (DOYU) initiated with an Overweight at JPMorgan. 3. Myovant Sciences (MYOV) initiated with a Buy at Goldman Sachs. 4. Anaplan (PLAN) initiated with an Outperform at RBC Capital. 5. Alphatec (ATEC) initiated with a Buy at Canaccord. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/19/19
JMPS
11/19/19
NO CHANGE
Target $34
JMPS
Outperform
JMP boosts Myovant price target to $34 after 'compelling' prostate cancer data
JMP Securities analyst Jason Butler raised his price target for Myovant Sciences to $34 from $25 saying the company's "compelling" Phase 3 results in prostate cancer "clearly demonstrate" the clinical value of relugolix. The stock in afternoon trading is up 99%, or $6.14, to $12.20. The analyst views today's data as the best case outcome for relugolix and he increased his probability of approval in prostate cancer to 90% and peak penetration from 6% to 15%. The results support that relugolix is "clearly superior" to GnRH agonists including leuprolide, and also de-risk regulatory approvals in the U.S. and Europe, Butler tells investors in a research note. He reiterates an Outperform rating on shares of Myovant Sciences.
11/19/19
GSCO
11/19/19
NO CHANGE
Target $20
GSCO
Buy
Myovant Sciences price target raised to $20 from $18 at Goldman Sachs
Goldman Sachs analyst Paul Choi reiterated a Buy rating on Myovant Sciences and raised his price target on the shares to $20 from $18 after the company reported "positive" data from its Phase 3 HERO trial of relugolix in men with advanced prostate cancer. Choi said the trial results will likely facilitate FDA approval following the expected NDA filing in the second quarter of 2020 and patient usage over leuprolide for those seeking an oral treatment with potential superiority for intermittent therapy and/or superior cardiac outcomes. The analyst added that he is looking to the first half of 2020 for full data details in a publication and the third quarter for data on time to castration resistance. Otherwise, Choi said he expects Myovant commercial execution to come into investor focus given the pricing/reimbursement landscape for existing offerings and with relugolix now de-risked in two of its three indications.
PIRS Pieris Pharmaceuticals
$3.93

0.03 (0.77%)

05/13/19
BARD
05/13/19
INITIATION
Target $5
BARD
Outperform
Pieris Pharmaceuticals initiated with an Outperform at Baird
Baird analyst Madhu Kumar initiated Pieris Pharmaceuticals with an Outperform and $5 price target.
05/14/19
BARD
05/14/19
INITIATION
Target $5
BARD
Outperform
Pieris Pharmaceuticals initiated with an Outperform at Baird
Baird analyst Madhu Kumar initiated Pieris Pharmaceuticals with an Outperform rating and $5 price target, saying he believe's Pieris' anticalin platform has the potential to disrupt biologic therapies in the respiratory and oncology spaces. The analyst called out the company's Phase 1 single ascending dose results for anti-interleukin-4 receptor a Ac PRS060 as potentially validating the drug's utility in asthma and serve as a positive catalyst for shares.
07/29/19
WBLR
07/29/19
NO CHANGE
WBLR
Outperform
Updates 'very positive' for upcoming Pieris presentation, says William Blair
Pieris Pharmaceuticals (PIRS) will present Phase Ib safety and efficacy results with PRS-060, an inhaled IL-4R alpha inhibitor, at the upcoming European Respiratory Society International Congress, held September 28 through October 2, William Blair analyst Matt Phipps tells investors in a research note. The poster presentation to be presented on October 1 is titled, "Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma," the analyst point out. In addition, AstraZeneca (AZN) plans to initiate a Phase II trial with AZD1402/PRS-060 in the second half of this year, according to its recent earnings presentation, adds Phipps. He views these updates as "very positive" for the upcoming presentation, and believes PRS-060 has "significant potential" in the treatment of asthma patients. Phipps keeps an Outperform rating on Pieris Pharmaceuticals.
07/30/19
BARD
07/30/19
DOWNGRADE
Target $5
BARD
Neutral
Pieris Pharmaceuticals downgraded to Neutral from Outperform at Baird
Baird analyst Madhu Kumar downgraded Pieris Pharmaceuticals to Neutral from Outperform with an unchanged price target of $5.
MYL Mylan
$18.89

0.365 (1.97%)

11/07/19
MSCO
11/07/19
DOWNGRADE
Target $18
MSCO
Equal Weight
Mylan downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst David Risinger downgraded Mylan to Equal Weight from Overweight with an $18 price target.
11/07/19
MSCO
11/07/19
DOWNGRADE
Target $18
MSCO
Equal Weight
Mylan downgraded to Equal Weight on growth uncertainty at Morgan Stanley
As previously reported, Morgan Stanley analyst David Risinger downgraded Mylan to Equal Weight from Overweight with a price target of $18, down from $25. He has become more conservative in his estimates after competing U.S. generic businesses missed estimates in the past two days, which he thinks may be indicative of ongoing industry pressures, Risinger tells investors. After management's Q3 call comments implied uncertainty about 2020 and beyond, and three other generic businesses reported disappointing results over the past two days, Risinger has cut his out-year forecasts for revenue and margins. His long-term EPS is now 6% below consensus for Mylan, the analyst noted.
11/07/19
11/07/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Twitter (TWTR) downgraded to Underperform from In Line at Evercore ISI with analyst Kevin Rippey citing his view that 2018 represented a period of "unsustainably high" margins as Twitter reaped the benefits of a period of sustained underinvestment. 2. Mylan (MYL) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst David Risinger sayinge has become more conservative in his estimates after competing U.S. generic businesses missed estimates in the past two days, which he thinks may be indicative of ongoing industry pressures. 3. Expedia (EXPE) downgraded to Neutral from Overweight at Piper Jaffray and to Neutral from Buy at DA Davidson and BofA/Merrill. 4. Bloomin' Brands (BLMN) downgraded to Neutral from Overweight at JPMorgan with analyst John Ivankoe citing valuation. 5. Papa John's (PZZA) downgraded to Neutral from Buy at MKM Partners with analyst Brett Levy saying the company has generated its first positive domestic comps in two years while laying the foundation for a "potential turnaround," but after a 43% run-up in the stock price since August 23, he believes the valuation warrants a neutral stance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/19/19
MSCO
11/19/19
NO CHANGE
Target $262
MSCO
Underweight
Mylan only IPR challenger remaining for Biogen's Tecfidera, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that the U.S. Patent and Trademark Appeal Board issued an order indicating that Sawai and Biogen (BIIB) have settled their disputes regarding the key Biogen patent protecting Tecfidera, which he said leaves Mylan (MYL) as the only other IPR challenger. Although he expects investors to view this as a step in the right direction, he still sees the IPR continuing with Mylan remaining a key overhang on Biogen shares. Even if Mylan and Biogen were to settle, the PTAB will likely continue to issue a final written decision by February 2020 since the IPR has had an oral hearing, which puts the patent at risk, said Harrison. He keeps an Underweight rating on Biogen shares.
RCKT Rocket Pharmaceuticals
$19.22

0.88 (4.80%)

10/24/19
PIPR
10/24/19
NO CHANGE
Target $35
PIPR
Overweight
Rocket Pharmaceuticals data update 'incrementally positive,' says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren says Rocket Pharmaceuticals today announced "incrementally positive" long-term follow-up data from four Fanconi anemia patients treated with RP-L102 using the first generation Process A. Most importantly, the updated data provide long-term evidence of "increasing and durable" engraftment and stabilization in blood counts in the absence of cytotoxic conditioning, Van Buren tells investors in a research note. The analyst believes RP-L102 is "looking more and more like a complete replacement for sub-optimal HSCT." RP-L102 appears to be the first therapy to have long-term, disease modifying potential in Fanconi anemia patients and could achieve ~$500M in peak sales, according to Van Buren. He reiterates an Overweight rating on the shares with a $35 price target.
11/05/19
CHDN
11/05/19
INITIATION
Target $30
CHDN
Buy
Rocket Pharmaceuticals initiated with a Buy at Chardan
Chardan analyst Geulah Livshits initiated coverage of Rocket Pharmaceuticals with a Buy rating and $30 price target citing the potential of its blended ex vivo/in vivo gene therapy pipeline. The analyst said Rocket is rapidly advancing its pipeline with 4 company sponsored INDs cleared within the last 12 months to provide transformative treatments for patients with rare monogenic diseases and shareholder value through inflection points.
11/07/19
PIPR
11/07/19
NO CHANGE
Target $35
PIPR
Overweight
Rocket Pharmaceuticals data by year-end to boost shares, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren believes "positive" Process B Fanconi anemia data and positive initial Phase I LAD-1 data by year-end will boost shares of Rocket Pharmaceuticals higher. Sales from Rocket's lentiviral pipeline alone could exceed $1B, while the Danon's disease program has blockbuster potential of $3B or more, Van Buren tells investors in a research note. He keeps an Overweight rating on Rocket Pharmaceuticals with a $35 price target following the company's Q3 results.
11/18/19
PIPR
11/18/19
NO CHANGE
Target $35
PIPR
Overweight
Rocket may be next leading lentiviral vector company, says Piper Jaffray
After hosting an investor lunch with management, Piper Jaffray analyst Tyler Van Buren says Rocket Pharmaceuticals could "soon take the spot as the next leading lentiviral vector company." By year-end, the analyst expects early clinical observations from the two Process B Fanconi anemia patients and the one LAD-1 patient to give insight into the likely approvability of these programs. The Fanconi anemia update doesn't just de-risk an addressable opportunity that is approaching $1B, it validates Rocket's broader lentiviral gene therapy platform, Van Buren tells investors in a research note. He keeps an Overweight rating on the shares with a $35 price target.
CBAY CymaBay
$1.66

-0.01 (-0.60%)

11/26/19
RAJA
11/26/19
DOWNGRADE
RAJA
Market Perform
CymaBay double downgraded at Raymond James after seladelpar setback
As previously reported, Raymond James analyst Steven Seedhouse double downgraded CymaBay to Market Perform from Strong Buy following the "unexpected setback" for seladelpar that has resulted in the company terminating or halting all programs for the drug. He cut his view on the probability of success in primary biliary cholangitis, the remaining indication being studied, to 25% from 90% and sees uncertainty for any path forward for the lead program, Seedhouse tells investors.
11/26/19
ROTH
11/26/19
DOWNGRADE
Target $2
ROTH
Neutral
CymaBay downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Yasmeen Rahimi downgraded CymaBay to Neutral from Buy with a price target of $2, down from $22, following the company's announcement of a clinical halt for seladelpar and subsequent call providing more details of histology findings. She walked away from CymaBay update call with more understanding of the atypical histological findings, but still remains uncertain regarding the cause and how the clinical halt will be resolved, Rahimi tells investors. She prefers to step to the sidelines while awaiting more clarity regarding timelines and casualty, the analyst added.
11/26/19
11/26/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Hold from Buy at China Renaissance with analyst Carson Ng citing valuation. 2. CenterPoint Energy (CNP) downgraded to Market Perform from Outperform at Wells Fargo with analyst Sarah Akers saying she now now assumes the company will need $2.5B in equity funding in reaction to negative developments including, most recently, the Public Utilities Commission of Texas' cost of capital decision. 3. CymaBay (CBAY) was downgraded to Market Perform from Strong Buy at Raymond James, to Neutral from Overweight at Cantor Fitzgerald, as well as to Neutral from Buy at H.C. Wainwright and Roth Capital. 4. Molson Coors (TAP) downgraded to Market Perform from Outperform at BMO Capital with analyst Amit Sharma saying Molson's "persistently low" valuation and high free cash flow yield has failed to entice investors as its "structurally compromised" sales growth has been "too high a hurdle," even for deep-value investors. 5. Comerica (CMA) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Ken Zerbe saying he sees "far more" net interest margin compression at Comerica by the end of 2020 than the median he expects at its peers. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/26/19
HCWC
11/26/19
NO CHANGE
HCWC
Favorable safety a positive for Genfit's elafibranor, says H.C. Wainwright
After Genfit (GNFT) this morning announced that the Data Safety Monitoring Board issued a positive recommendation for the continuation, without any modifications, of the Resole-It Phase 3 trial evaluating elafibranor in nonalcoholic steatohepatitis, H.C. Wainwright analyst Ed Arce noted this is the seventh such report affirming the favorable safety profile of elafibranor. After CymaBay (CBAY) announced yesterday that it has halted all clinical development of its lead drug seladelpar, Arce also noted that there have been no cases of interface hepatitis seen in all trials to date with elafibranor. "One less competitor only benefits the other players in the space, and the two remaining PPARs, especially elafibranor," added Arce. Commenting further on Intercept's (ICPT) announcement yesterday that the FDA has accepted its NDA for obeticholic acid for accelerated approval for the treatment of fibrosis due to NASH, Arce said he sees "two very differentiated profiles with the first two drugs likely to be approved for NASH," namely Intercept's OCA and Genfit's elafibranor. The analyst, who concludes with the assertion that the "overall efficacy, safety and tolerability profile of elafibranor is hands down superior to that of OCA," keeps a Buy rating and $58 price target on Genfit shares.
NBIX Neurocrine
$118.67

1.08 (0.92%)

09/25/19
RBCM
09/25/19
NO CHANGE
RBCM
Outperform
Neurocrine approval in Huntington's could add upside, says RBC Capital
RBC Capital analyst Brian Abrahams noted that a posting to the ClinicalTrials.gov site revealed that Neurocrine Biosciences is studying the use of Ingrezza in the treatment of Huntington's Chorea. He thinks that Ingrezza's strong position in the tardive dyskinesia market could be a boon for the drug in a new indication and predicts that eventual approval in Huntington's could potentially add as much as an added 20% to out-year revenue estimates for the drug. Abrahams keeps an Outperform rating on Neurocrine shares.
10/04/19
GUGG
10/04/19
NO CHANGE
GUGG
Guggenheim positively biased on Biotech heading into earnings
Guggenheim analysts Whitney Ijem, Etzer Darout, Yatin Suneja and Michael Schmidt offered a preview for their joint Biotech coverage ahead of the group's earnings reporting season. Biotech stocks continued their downward trend in the quarter amid negative market sentiment and the analysts think the bar for companies to raise 2019 guidance again may be a bit higher following increases in FY19 consensus estimates on the heels of strong Q2 earnings results. However, they are postively biased on the group and have confidence in FY19 guidance and estimates, the analysts said. They see Alexion (ALXN), Biogen (BIIB), Genmab (GMAB), GW Pharmaceuticals (GWPH), Incyte (INCY), Neurocrine (NBIX), Regeneron (REGN) and Seattle Genetics (SGEN) as well positioned relative to expectations, Ijem, Darout, Suneja and Schmidt tell investors.
11/05/19
PIPR
11/05/19
NO CHANGE
Target $116
PIPR
Overweight
Neurocrine price target raised to $116 from $111 at Piper Jaffray
Piper Jaffray analyst David Amsellem raised his price target for Neurocrine Biosciences to $116 from $111 saying the company reported another "impressive quarter" for Ingrezza. He continues to believe that peak U.S. sales potential in the $2B-plus neighborhood are realistic and reiterates an Overweight rating on the shares.
TCDA Tricida
$39.62

0.09 (0.23%)

04/01/19
EAMC
04/01/19
NO CHANGE
Target $58
EAMC
Buy
Tricida price target raised to $58 from $37 at Empire
05/24/19
NEED
05/24/19
INITIATION
Target $50
NEED
Buy
Tricida initiated with a Buy at Needham
Needham analyst Alan Carr initiated Tricida with a Buy rating and a price target of $50, citing the company's Phase 3 data for its Chronic Kidney Disease veverimer drug demonstrating a "clinically and statistically significant impact" on serum bicarbonate and life measures. The analyst expects the drug to be approved in the back half of 2020 and also to get confirmation of a benefit on renal outcomes from the ongoing Phase 3b trial by 2023, modeling $1.5B in peak U.S. sales by 2034.
06/26/19
GSCO
06/26/19
INITIATION
GSCO
Buy
Tricida initiated with a Buy at Goldman Sachs
06/27/19
GSCO
06/27/19
INITIATION
Target $48
GSCO
Buy
Goldman starts 'potential game-changer' Tricida with Buy, $48 price target
Goldman Sachs analyst Graig Suvannavejh last night initiated coverage of Tricida with a Buy rating and $48 price target. The analyst views the company as a "potential game-changer" in chronic kidney disease. Its lead asset, veverimer, has already reported positive Phase 3 data in metabolic acidosis, and a new drug application is expected in the second half of 2019, Suvannavejh tells investors in a research note. The analyst sees a "significant" commercial opportunity, projecting $2B in peak year 2033 sales.
NTLA Intellia Therapeutics
$17.67

0.59 (3.45%)

07/09/19
07/09/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Chewy (CHWY) was initiated with an Outperform at William Blair and Wells Fargo, an Overweight at JPMorgan, a Buy at BofA/Merrill and UBS, an Equal Weight at Morgan Stanley and Barclays, a Market Perform at Raymond James, a Sector Perform at RBC Capital, a Hold at Jefferies, and a Neutral at Nomura Instinet. 2. Intellia Therapeutics (NTLA) initiated with an Outperform at Baird. 3. Slack Technologies (WORK) initiated with a Perform at Oppenheimer. 4. AAR Corp. (AIR) initiated with a Buy at Stifel. 5. Vista Outdoor (VSTO) initiated with a Buy at Lake Street. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/01/19
RAJA
11/01/19
UPGRADE
Target $24
RAJA
Outperform
Intellia upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Steven Seedhouse upgraded Intellia Therapeutics to Outperform from Market Perform with a $24 price target.
11/01/19
RAJA
11/01/19
UPGRADE
Target $24
RAJA
Outperform
Intellia Therapeutics upgraded to Outperform at Raymond James
Raymond James analyst Steven Seedhouse upgraded Intellia Therapeutics to Outperform from Market Perform with a $24 price target. In a research note to investors, Seedhouse says Intellia's NTLA-2001 is poised to benefit from the "heavy lifting" Pfizer (PFE) is doing commercially with Vyndaqel in ATTR-cardiomyopathy, adding that Intellia is also advancing manufacturing related activities in support of a Phase 1 trial for engineered cell program WT1-TCR in AML. The analyst also says Intellia's lead gene editing program, NTLA-2001 has "really good" primate data showing TTR knockdown potentially better than Alnylam's (ALNY) patisiran. He expects the market will already start to impute downstream clinical benefit for NTLA-2001 after only a few patients with initial TTR knockdown data, because of the collective data for Ionis Pharmaceuticals' (IONS) inotersen and Alnylam's patisiran showing knockdown is relevant.
12/03/19
RAJA
12/03/19
DOWNGRADE
RAJA
Market Perform
Audentes downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Steven Seedhouse downgraded Audentes Therapeutics (BOLD) to Market Perform from Outperform after the company agreed to be aquired by Astellas Pharma (ALPMY) for $60 per share. The analyst, who views the deal as "another bullish domino for genetic medicine," expects shares of Editas Medicine (EDIT), Intellia Therapeutics (NTLA) and Crispr Therapeutics (CRSP) to "benefit from the optics."
ALKS Alkermes
$21.24

0.98 (4.84%)

11/01/19
HCWC
11/01/19
NO CHANGE
Target $26
HCWC
Neutral
Alkermes price target lowered to $26 from $28 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao lowered his price target for Alkermes (ALKS) to $26 from $28 and reiterates a Neutral rating on the shares. With announced rationalization of the cost structure and launch of Vumerity as well as expected launch of ALKS-3831, the analyst expects the company to achieve non-GAAP profitability. He thinks Vumerity could eventually represent 25%-30% of the Tecfidera/Vumerity franchise, although he would like to see how aggressively Biogen (BIIB) promotes Vumerity before ascribing that much value. However, Tsao is doubtful that earnings based on the launches of Vumerity and ALKS-3831 can command an earnings multiple "that can take shares meaningfully" higher. Sentiment around ALKS-4230 could be the key driver of Alkermes shares over the next two years, the analyst adds.
11/11/19
MSCO
11/11/19
NO CHANGE
Target $20
MSCO
Equal Weight
Alkermes data at SITC too early to assess 4230 potential, says Morgan Stanley
Morgan Stanley analyst David Risinger noted that Alkermes presented new data from the company's ARTISTRY clinical development program related to ALKS 4230 at the Society for Immunotherapy of Cancer annual meeting. While he noted "encouraging signals" such as a patient with pancreatic cancer with stable disease on monotherapy for six months as well as two partial responses from patients on combination therapy, there were also "disappointing signals" such as the fact that no patients had partial response or complete response in the monotherapy dose escalation stage, Risinger said. Overall, he thinks that data presented at SITC were "too preliminary to assess" the potential of 4230 and he looks forward to future updates, said Risinger, who keeps an Equal Weight rating on Alkermes shares with a $20 price target.
11/18/19
STFL
11/18/19
NO CHANGE
Target $23
STFL
Hold
Alkermes made 'nice strategic move' in buying Rodin, says Stifel
Stifel analyst Paul Matteis views Alkermes' acquisition of Rodin as a "nice strategic move," saying it offers an entry into an interesting emerging area of neuroscience at a reasonable price. Rodin's portfolio could be applied to a wide array of central nervous system indications where synaptic loss or dysfunction is core to the pathology, including Alzheimer's, Huntington's or even psychiatric ailments like depression and schizophrenia, Matteis tells investors in a research note. However, this is an early stage deal, and unlikely to be immediately stock moving, the analyst adds. Matteis keeps a Hold rating on Alkermes with a $23 price target.
11/18/19
PIPR
11/18/19
NO CHANGE
Target $22
PIPR
Neutral
Alkermes deal strengthens early-stage pipeline, says Piper Jaffray
Alkermes strengthened its early-stage pipeline with the acquisition of Rodin Therapeutics and its oral, selective histone deactelyase inhibitors platform, Piper Jaffray analyst Danielle Brill tells investors in a research note. Building out its research and development efforts in the neurodegenerative space will allow Alkermes to leverage its existing expertise, adds the analyst, who views the company's effort to expand its pipeline positively. However, Brill notes that the acquired assets are still in very early development "and won't be value-creating for some time." To get more constructive on the shares, the analyst wants to see Alkermes add clinical stage assets "that are more de-risked" to its pipeline. Brill keeps a Neutral rating on the shares with a $22 price target.

TODAY'S FREE FLY STORIES

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

, SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SLV

iShares Silver Trust

$16.82

0.04 (0.24%)

GLD

SPDR Gold Shares

$146.59

0.29 (0.20%)

FXE

Euro Currency Trust

$105.10

-0.43 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSFY

Ubisoft

$0.00

(0.00%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
Periodicals
Ubisoft to restructure editorial team after difficult 2019, VGC reports »

Ubisoft intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Feb

IMVT

Immunovant

$17.04

-0.01 (-0.06%)

17:27
01/17/20
01/17
17:27
01/17/20
17:27
Syndicate
Breaking Syndicate news story on Immunovant »

Immunovant files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBLT

ToughBuilt

$0.33

-0.0255 (-7.11%)

17:20
01/17/20
01/17
17:20
01/17/20
17:20
Syndicate
ToughBuilt files to sell common stock, no amount given »

Maxim acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYO

Myomo

$0.32

0.0062 (1.98%)

17:18
01/17/20
01/17
17:18
01/17/20
17:18
Conference/Events
Myomo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRRA

Sierra Oncology

$0.40

-0.02 (-4.76%)

17:14
01/17/20
01/17
17:14
01/17/20
17:14
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRNE

Sorrento Therapeutics

$4.26

-0.15 (-3.40%)

17:10
01/17/20
01/17
17:10
01/17/20
17:10
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$3.45

-0.1 (-2.82%)

17:01
01/17/20
01/17
17:01
01/17/20
17:01
Hot Stocks
Akers Biosciences reaches settlement agreements on two derivative actions »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.09

-0.18 (-4.22%)

16:40
01/17/20
01/17
16:40
01/17/20
16:40
Hot Stocks
Encana receives court approval for reorganization »

Encana Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

MBRX

Moleculin Biotech

$0.96

0.0122 (1.29%)

16:38
01/17/20
01/17
16:38
01/17/20
16:38
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$20.07

-0.225 (-1.11%)

, BT

BT Group

$0.00

(0.00%)

16:37
01/17/20
01/17
16:37
01/17/20
16:37
Periodicals
BT, Vodafone consider urging PM Johnson not to ban Huawei in U.K., Reuters says »

BT Group (BT) and…

VOD

Vodafone

$20.07

-0.225 (-1.11%)

BT

BT Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/17/20
01/17
16:30
01/17/20
16:30
Options
Preliminary option volume of 28.7M today »

Preliminary option volume…

NSCO

Nesco Holdings

$5.12

0.025 (0.49%)

16:26
01/17/20
01/17
16:26
01/17/20
16:26
Syndicate
Nesco Holdings requests withdrawal of registration statement »

Nesco Holdings has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$18.54

-0.075 (-0.40%)

, CMCSA

Comcast

$47.48

0.62 (1.32%)

16:20
01/17/20
01/17
16:20
01/17/20
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

The major averages were…

GPS

Gap

$18.54

-0.075 (-0.40%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

CMCSK

Comcast

$0.00

(0.00%)

PLAY

Dave & Buster's

$47.35

5.3 (12.60%)

KKR

KKR

$31.20

0.7 (2.30%)

BA

Boeing

$324.11

-7.89 (-2.38%)

JNJ

Johnson & Johnson

$149.07

0.82 (0.55%)

SWK

Stanley Black & Decker

$172.63

2.18 (1.28%)

TWOU

2U

$22.84

1.05 (4.82%)

BE

Bloom Energy

$9.70

0.43 (4.64%)

MGPI

MGP Ingredients

$38.16

-14.74 (-27.86%)

FAST

Fastenal

$36.77

-0.55 (-1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 20

    Jan

  • 22

    Jan

  • 23

    Jan

  • 29

    Jan

  • 29

    Jan

  • 31

    Jan

  • 26

    Feb

  • 27

    Feb

  • 09

    Mar

  • 17

    Mar

APLS

Apellis

$40.43

0.03 (0.07%)

16:18
01/17/20
01/17
16:18
01/17/20
16:18
Hot Stocks
Apellis CEO sells 30.6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
01/17/20
01/17
16:17
01/17/20
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
01/17/20
01/17
16:16
01/17/20
16:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
01/17/20
01/17
16:15
01/17/20
16:15
General news
Treasury Market Summary »

Treasury Market Summary:…

LGC

Legacy Acquisition Corp

$10.33

(0.00%)

16:08
01/17/20
01/17
16:08
01/17/20
16:08
Hot Stocks
Legacy Acquisition Corp extends date to consummate proposed business combination »

Legacy Acquisition Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNUS

Genius Brands

$0.33

-0.015 (-4.41%)

16:04
01/17/20
01/17
16:04
01/17/20
16:04
Syndicate
Breaking Syndicate news story on Genius Brands »

Genius Brands files $50M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$90.21

1.28 (1.44%)

16:04
01/17/20
01/17
16:04
01/17/20
16:04
Periodicals
Best Buy board opens investigation into CEO's personal conduct, WSJ says »

The board of Best Buy is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.